Know Labs, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Know Labs, Inc. is a medical device and technology company specializing in the development and commercialization of proprietary non-invasive diagnostic technologies based on radiofrequency dielectric spectroscopy and radio-microwave spectroscopy. The company’s platform technology uses electromagnetic energy to identify and measure molecular compositions in vivo, enabling non-invasive health monitoring. Know Labs offers core products including sensor technology optimized for continuous blood glucose monitoring, with its first commercial application being a wearable device that provides real-time glucose level information to assist diabetes management. The technology platform is versatile, enabling integration into wearable, mobile, or benchtop form factors for numerous applications in healthcare, pharmaceuticals, food safety, agriculture, and security sectors. Founded in 1998 and headquartered in Seattle, Washington, Know Labs operates primarily in the United States and targets medical diagnostics and sensor technology industries. Recent major changes include a strategic acquisition in March 2024 led by investor Greg Kidd, involving a $125 million infusion, which has strengthened the company's financial position and leadership team. In 2025, the company implemented a 1-for-40 reverse stock split to meet exchange listing compliance and has launched the Know Labs Technology Licensing (KTL) initiative, aiming to accelerate commercialization of its platform through partnerships and licensing agreements. The company also plans to rename itself USBC, Inc., with a new corporate focus on a blockchain-based token offering linked to its strategic vision, while retaining a division dedicated to diagnostic research and development. Know Labs continues advancing its flagship non-invasive glucose monitor with ongoing clinical validation, algorithm development, and regulatory milestone pursuits toward FDA clearance. These strategic and operational initiatives position Know Labs as a pioneer in non-invasive medical diagnostics transforming traditional blood testing methods.
Know Labs (NYSEAMERICAN:KNW) Shares Up 3.8% – Should You Buy?
Know Labs (NYSEAMERICAN:KNW) Stock Price Up 3.8% – Still a Buy?
Know Labs (NYSEAMERICAN:KNW) Shares Up 3.8% – What’s Next?
Greg Kidd & Know Labs Announce Closing of [$100]M Strategic Acquisition
Know Labs, Inc. Announces Adjournment of Special Meeting of Stockholders
Know Labs Reminds its Stockholders to Vote Ahead of the Special Meeting on July 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
KNOW LABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Know Labs, Inc. - KNW
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW and HLGN on Behalf of Shareholders
This stock rallies over 200% on Bitcoin-led buyout of parent company
KNW Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Know Labs, Inc. Is Fair to Shareholders
Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy
Know Labs Sensor Non-Invasively Identifies pH Levels in Real Time
Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Know Labs Announces Cancellation of Special Meeting of Stockholders
Know Labs Announces Reverse Stock Split Effective February 19, 2025
Know Labs, Inc. to Report First Quarter FY 2025 Results
Know Labs Responds to NYSE Commencement of Proceedings to Delist
Know Labs Launches Know Labs Technology Licensing (KTL)
Know Labs, Inc. Announces $300K Registered Direct Offering